Marketdash
Back to News

Medtronic Beats Earnings Expectations, But Analysts Remain Cautious

MarketDash Editorial Team
19 days ago
Medtronic delivered a strong second quarter with cardiovascular and diabetes units leading the charge, prompting management to raise guidance. Despite the momentum, analysts are holding back on upgrades as they wait for sustained proof.

Medtronic PLC (MDT) shares edged higher in early Wednesday trading after the medical device giant delivered fiscal second-quarter results that beat expectations across the board. Revenue came in at $8.961 billion, topping the $8.867 billion consensus, while non-GAAP earnings of $1.36 per share exceeded analyst estimates of $1.31.

The real story here is momentum. Organic revenue growth got a boost from two key business segments: Cardiovascular and Diabetes. That strength prompted management to raise their full-year organic revenue growth outlook to around 5.5%, up from the previous projection of roughly 5%. They also nudged up the bottom end of their earnings guidance to $5.62-$5.66 per share, from the prior $5.60-$5.66 range.

Analysts See Promise, But Want More Proof

Needham analyst Mike Matson kept his Hold rating on the stock but acknowledged the improving trajectory. "We believe that MDT is in the early stages of a strong product cycle, and we are encouraged by its improved growth in F2Q26," he wrote in his note to clients.

BTIG analyst Ryan Zimmerman also maintained a Neutral rating, offering a more nuanced take. He noted that the Cardiovascular and Diabetes businesses delivered robust results that offset softer performance in Medical-Surgical and Neuroscience. "In our view, this was MDT's best quarter in a while even as margin performance was mixed," Zimmerman wrote.

Here's the catch: while gross margins improved and beat estimates, operating margins actually contracted and missed consensus. The reason? Medtronic is ramping up operating investments to fuel that stronger growth everyone's hoping for. Zimmerman pointed out that the stock already reflects the improved quarterly performance and pipeline optimism, which likely explains his wait-and-see stance.

Stock Approaching 52-Week High

Medtronic shares were trading up 0.13% at $100.93 on Wednesday, inching closer to the 52-week high of $102.48. The stock has clearly benefited from the positive earnings surprise and raised guidance, but analysts seem to be waiting for sustained execution before getting more enthusiastic.

Back to News

Medtronic Beats Earnings Expectations, But Analysts Remain Cautious

MarketDash Editorial Team
19 days ago
Medtronic delivered a strong second quarter with cardiovascular and diabetes units leading the charge, prompting management to raise guidance. Despite the momentum, analysts are holding back on upgrades as they wait for sustained proof.

Medtronic PLC (MDT) shares edged higher in early Wednesday trading after the medical device giant delivered fiscal second-quarter results that beat expectations across the board. Revenue came in at $8.961 billion, topping the $8.867 billion consensus, while non-GAAP earnings of $1.36 per share exceeded analyst estimates of $1.31.

The real story here is momentum. Organic revenue growth got a boost from two key business segments: Cardiovascular and Diabetes. That strength prompted management to raise their full-year organic revenue growth outlook to around 5.5%, up from the previous projection of roughly 5%. They also nudged up the bottom end of their earnings guidance to $5.62-$5.66 per share, from the prior $5.60-$5.66 range.

Analysts See Promise, But Want More Proof

Needham analyst Mike Matson kept his Hold rating on the stock but acknowledged the improving trajectory. "We believe that MDT is in the early stages of a strong product cycle, and we are encouraged by its improved growth in F2Q26," he wrote in his note to clients.

BTIG analyst Ryan Zimmerman also maintained a Neutral rating, offering a more nuanced take. He noted that the Cardiovascular and Diabetes businesses delivered robust results that offset softer performance in Medical-Surgical and Neuroscience. "In our view, this was MDT's best quarter in a while even as margin performance was mixed," Zimmerman wrote.

Here's the catch: while gross margins improved and beat estimates, operating margins actually contracted and missed consensus. The reason? Medtronic is ramping up operating investments to fuel that stronger growth everyone's hoping for. Zimmerman pointed out that the stock already reflects the improved quarterly performance and pipeline optimism, which likely explains his wait-and-see stance.

Stock Approaching 52-Week High

Medtronic shares were trading up 0.13% at $100.93 on Wednesday, inching closer to the 52-week high of $102.48. The stock has clearly benefited from the positive earnings surprise and raised guidance, but analysts seem to be waiting for sustained execution before getting more enthusiastic.

    Medtronic Beats Earnings Expectations, But Analysts Remain Cautious - MarketDash News